Neumo­ra goes big with three PhI­II de­pres­sion stud­ies, new CEO from Ab­b­Vie’s C-suite

The wheels are rolling fast at Neumo­ra as the “Re­al­ly Big Neu­ro­science Com­pa­ny” nears three Phase III tri­als for its in­ves­ti­ga­tion­al de­pres­sion drug, read­ies a slate of oth­er clin­i­cal stud­ies and woos a new CEO from Big Phar­ma.

Neumo­ra said Tues­day morn­ing it hired Hen­ry Gose­bruch as pres­i­dent and CEO. Gose­bruch, Ab­b­Vie’s for­mer chief strat­e­gy of­fi­cer, joined Ju­ly 3 and takes the place of Paul Berns, who tran­si­tioned to ex­ec­u­tive chair.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER